Price
Target price
€2.65
€2.65
0.230%
0.006
0.230%
€4.62
19.09.24 / Tradegate
WKN: A3C4ZC / Symbol: XERS / Name: Xeris Biopharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xeris Biopharma Holdings Inc. Stock
The Xeris Biopharma Holdings Inc. stock is trending slightly upwards today, with an increase of €0.006 (0.230%) compared to yesterday's price.
Currently there is a rather positive sentiment for Xeris Biopharma Holdings Inc. with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 4 € shows a very positive potential of 51.06% compared to the current price of 2.65 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 0.230% | 2.636% | 8.082% | 41.604% | 22.593% | 22.820% | - |
| Evolus Inc | 0.690% | 8.209% | 15.079% | 72.619% | 60.221% | 116.418% | - |
| Ardelyx Inc. | 0.300% | -4.516% | -0.739% | 42.819% | -7.093% | 375.221% | 21.783% |
| Coherus Bioscien. | -2.770% | -12.403% | -10.907% | -75.986% | -66.546% | -93.220% | -94.772% |
Comments
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock, down previously from $4.00.
Show more
Ratings data for XERS provided by MarketBeat
